Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834133 | PMC |
| http://dx.doi.org/10.1016/j.jtcvs.2020.05.081 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A review of methodologic & data considerations for vaccine safety surveillance in the wake of the COVID-19 pandemic.
Vaccine
September 2025
Brighton Collaboration, The Task Force for Global Health, Atlanta, GA, United States of America.
Vaccine safety surveillance systems are vital for the post-market safety monitoring of novel and well-established vaccines, given the sample size, representativeness and follow-up time in clinical trials. The introduction of COVID-19 vaccines during the SARS-CoV-2 pandemic presented unprecedented challenges for safety surveillance. Here, we discuss methodologic considerations for epidemiologic study design and real world data for passive and active surveillance systems for COVID-19 vaccines in the United States (U.
View Article and Find Full Text PDFAn Electronic Health Record-Wide Association Study to identify populations at increased risk of E. coli bloodstream infections.
J Infect
September 2025
Nuffield Department of Medicine, University of Oxford, Oxford, UK; The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK; The National Institute for Health Research Oxford Bi
Objectives: Escherichia coli bacteraemias have been under mandatory surveillance in the UK for fifteen years, but cases continue to rise. Systematic searches of all features present within electronic healthcare records (EHRs), described here as an EHR-wide association study (EHR-WAS), could potentially identify under-appreciated factors that could be targeted to reduce infections.
Methods: We used data from Oxfordshire, UK, and an EHR-WAS method developed for use with large-scale COVID-19 data to estimate associations between E.
Green Tea Catechins and COVID-19: Epidemiological Trends and Therapeutic Perspectives.
Curr Pharm Des
September 2025
Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Introduction: Pharmacological studies in vitro demonstrate the preventive and therapeutic potential of green tea and its constituent epigallocatechin-3-gallate (EGCG) in the fight against coronavirus disease 2019 (COVID-19). Previously reported correlations between per capita green tea consumption and COVID-19 morbidity/mortality suggest similar effects in vivo. Considering that some recent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) sub-variants are less influenced by EGCG, this study aimed to determine whether this affects the aforementioned correlations, focusing on comparisons between the periods before (2021) and after (2022-2024) the emergence of the Omicron variant.
View Article and Find Full Text PDFReal-World Analysis of Potential Drug-Drug Interactions with Nirmatrelvir/Ritonavir Based on the Hospital Prescription Analysis (HPA) Database in 9 Cities of China.
Infect Drug Resist
August 2025
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
Purpose: To determine the real-world patterns and extent of potential drug-drug interactions (DDIs) related to nirmatrelvir/ritonavir (NMVr) in China.
Patients And Methods: Data on NMVr-treated patients from over 160 hospitals across 9 Chinese cities from January 2022 to December 2023 were extracted from the Hospital Prescription Analysis (HPA) database, which was established in Beijing in 1997 to promote rational medication use in China. Grade C, D and X DDIs from the Lexicomp database were defined as clinically significant and analyzed in this study.
Estimates of SARS-CoV-2 vaccine effectiveness against outpatient medically attended SARS-CoV-2 infection from April 2023 through August 2024 in Hong Kong: A test-negative design study.
Vaccine
September 2025
World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region of China; Laboratory of Data Discovery for Health Limited, Hong Kong Science
Background: We aimed to estimate SARS-CoV-2 vaccine effectiveness (VE) against medically attended SARS-CoV-2 infection in Hong Kong.
Methods: We conducted a test-negative design study in individuals aged 5-64 years who presented with recent-onset (≤3 days) acute respiratory illness from April 2023 through to August 2024. Vaccination was defined as receipt of SARS-CoV-2 vaccine within 6 months of medical presentation, and for a sensitivity analysis, within 12 months of medical presentation.